META-ANALYSIS OF THE SAFETY DATA BETWEEN INFLIXIMAB BIOSIMILAR (CT-P13) AND INNOVATOR INFLIXIMAB IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS

被引：1
|
作者：
Park, W. [1 ]
Yoo, D. H. [2 ]
Suh, C. H. [3 ]
Shim, S. C. [4 ]
Lee, S. J. [5 ]
Lee, S. Y. [5 ]
Park, J. H. [5 ]
Bae, Y. M. [5 ]
Kim, S. H. [5 ]
Lee, S. G. [5 ]
机构：
[1] Inha Univ Hosp, Incheon, South Korea
[2] Hanyang Univ Hosp Rheumat Dis, Seoul, South Korea
[3] Ajou Univ Hosp, Suwon, South Korea
[4] Chungnam Natl Univ Hosp, Daejeon, South Korea
[5] Celltrion Inc, Incheon, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.4462
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0433
引用
收藏
页码：1039 / 1039
页数：1
相关论文
共 50 条
  • [1] EFFECTIVENESS AND SAFETY OF BIOSIMILAR INFLIXIMAB (CT-P13) IN A REAL-LIFE SETTING IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Codreanu, C.
    Sirova, K.
    Jarosova, K.
    Batalov, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 489 - 489
  • [2] A RETROSPECTIVE ANALYSIS OF LONG TERM SAFETY UP TO FIVE YEARS OF INFLIXIMAB BIOSIMILAR CT-P13 IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Kim, Tae-Hwan
    Lee, Shin-Seok
    Park, Won
    Song, Yeong Wook
    Suh, Chang-Hee
    Kim, Sookyoung
    Lee, Youngnam
    Yoo, DaeHyun
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1159 - 1160
  • [3] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
    Park, Won
    Miranda, Pedro
    Brzosko, Marek
    Wiland, Piotr
    Gutierrez-Urena, Sergio
    Mikazane, Helena
    Lee, Yeon-Ah
    Smiyan, Svitlana
    Lim, Mie-Jin
    Kadinov, Vladimir
    Abud-Mendoza, Carlos
    Son, YoungKi
    Yoo, Dae-Hyun
    Braun, Juergen
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3326 - 3326
  • [4] A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
    Tae-Hwan Kim
    Shin-Seok Lee
    Won Park
    Yeong Wook Song
    Chang-Hee Suh
    SooKyoung Kim
    Young Nam Lee
    Dae Hyun Yoo
    [J]. Clinical Drug Investigation, 2020, 40 : 541 - 553
  • [5] A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
    Kim, Tae-Hwan
    Lee, Shin-Seok
    Park, Won
    Song, Yeong Wook
    Suh, Chang-Hee
    Kim, SooKyoung
    Lee, Young Nam
    Yoo, Dae Hyun
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (06) : 541 - 553
  • [6] Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
    Yoo, Dae Hyun
    Prodanovic, Nenad
    Jaworski, Janusz
    Miranda, Pedro
    Ramiterre, Edgar
    Lanzon, Allan
    Baranauskaite, Asta
    Wiland, Piotr
    Abud-Mendoza, Carlos
    Oparanov, Boycho
    Smiyan, Svitlana
    Kim, HoUng
    Lee, Sang Joon
    Kim, SuYeon
    Park, Won
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 355 - 363
  • [7] WHAT INTRINSIC AND EXTRINSIC FACTORS AFFECT THE DEVELOPEMENT OF ANTI-DRUG ANTIBODY TO INNOVATOR INFLIXIMAB AND ITS BIOSIMILAR CT-P13 IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Braun, J.
    Park, W.
    Yoo, D. H.
    Suh, C. H.
    Shim, S. C.
    Lee, S. J.
    Lee, S. Y.
    Yun, J. H.
    Kim, S. Y.
    Lee, S. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 463 - 464
  • [8] Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis
    Codreanu, Catalin
    Sirova, Klara
    Jarosova, Katerina
    Batalov, Anastas
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (10) : 1763 - 1769
  • [9] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) Over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13.
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3319 - 3319
  • [10] Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness
    Jae Hee Cheon
    Seongsu Nah
    Hyoun Woo Kang
    Yun Jeong Lim
    Sang-Hoon Lee
    Sang Joon Lee
    Sung Hyun Kim
    Na Hyun Jung
    Jeong Eun Park
    Yeo Jin Lee
    Da Bee Jeon
    Yeon Mi Lee
    Jong Min Kim
    Sung-Hwan Park
    [J]. Advances in Therapy, 2021, 38 : 4366 - 4387
12345